Clinical trial protocols for vitamin D: essential pre-study data

Enroll participants whose baseline status is already adequate, leave body size and co-nutrient intake to chance, measure 25(OH)D on assays that disagree across laboratories, and deliver cholecalciferol through a food matrix whose stability has never been properly tested. The resulting null or ambiguous finding may still contain information, but it will be difficult to tell what the study actually tested.

Vitamin D fortification research is particularly vulnerable to this problem because the intervention is nutritional rather than pharmacological. The expected response depends on starting status, dose, absorption, body composition, season, dietary background and the analytical method used to measure the endpoint. None of these variables makes a trial impossible. Each one changes how confidently the result can be interpreted.

Robert P. Heaney’s work on nutrient trial design put this logic into a practical framework: measure baseline status, define the population that can plausibly respond, control major sources of variation and connect the intervention to a meaningful physiological target. A decade later, those principles remain less routine than they should be.

A defensible fortification protocol therefore begins before randomization. It begins with the data needed to decide whether the study population, laboratory method, vehicle and dose can answer the question being asked.

The Heaney Mandate: Baseline Status as an Inclusion Criterion

Heaney’s 2014 rules for nutrient trial design are not merely reminders to collect more variables. They change the logic of the study. Baseline nutrient status should be measured prospectively and used to define, or at least structure, the population entering the trial. It should not appear only as a descriptive value in Table 1 or as an afterthought in a post hoc subgroup analysis.

The reason is straightforward. A participant with a low starting 25(OH)D concentration has more room for a nutritional intervention to produce a measurable change than a participant who already has a concentration near the study’s intended physiological range. That does not mean a vitamin D-replete participant cannot respond. Supplementation or fortified food may still raise serum 25(OH)D in that group. The expected increase may be smaller, and a clinical outcome may be harder to shift, but the biological response is not categorically absent.

This distinction matters because many protocols quietly combine two different questions:

1. Can the intervention raise vitamin D status in people who begin with low status?

2. Can the intervention improve a clinical outcome in a population that is already broadly replete?

Those are not interchangeable questions. A trial designed for the first purpose needs a clear baseline threshold and a recruitment strategy capable of finding participants below it. A trial designed for the second needs a different effect-size assumption and should not be criticized simply because serum concentrations move less than they would in a deficient population.

For deficiency-focused fortification studies, a threshold below 50 nmol/L is commonly considered as part of the eligibility framework. The exact cutoff should be justified in the protocol, including the assay used, the population being recruited and whether the threshold is intended to identify deficiency, insufficiency or a subgroup with greater potential to benefit. A single number cannot resolve every clinical or policy question.

Baseline status should also influence randomization. If recruitment produces a broad distribution of 25(OH)D concentrations, randomization can be stratified by clinically meaningful bands. This prevents one arm from receiving a disproportionate share of participants with low or high starting values and makes it easier to model treatment response across the baseline range.

Baseline status does not decide the result, but it decides how much biological room the intervention has to show one.

The protocol should specify more than an enrollment cutoff. It should state:

• how and when blood samples will be collected;
• whether sampling is repeated when a result is close to the eligibility boundary;
• how recent supplement use will be recorded;
• whether season, latitude and sun-exposure patterns will be balanced;
• whether the primary analysis will include baseline 25(OH)D as a continuous predictor;
• and whether treatment effects will be examined separately across prespecified status categories.

This is not an argument for excluding every participant with adequate vitamin D status. Such a population may be exactly what a public-health intervention encounters in practice. It is an argument for making the target population explicit. A trial that mixes deficient and replete participants without a planned analysis may produce a valid average estimate, but the average can conceal a larger response in one subgroup and a smaller response in another.

The same principle applies to the dose. A daily intake of 600 IU may have a detectable effect in participants with low baseline status while producing a more modest change in participants who begin higher. If the protocol assumes one uniform response, it can understate the intervention’s effect in one group or overstate it in another.

Mitigating Confounding Variables: BMI and Nutrient Sufficiency

Baseline 25(OH)D is the headline variable, but body composition can substantially influence the relationship between intake and circulating concentration. Participants with obesity often have lower serum 25(OH)D concentrations and may show a smaller increase for a given dose than leaner participants. Proposed mechanisms include distribution into a larger volume of adipose tissue, differences in metabolism and differences in the relationship between administered dose and body size.

The practical conclusion is not that enrolling participants with a BMI above 30 kg/m² invalidates a study. It does not. Nor does obesity guarantee a flattened dose-response curve. The conclusion is that BMI can modify or confound the response and therefore needs to be measured, balanced and incorporated into the analysis.

A protocol has several defensible options:

• exclude higher-BMI participants when the scientific question is deliberately narrow;
• recruit across BMI categories and stratify randomization;
• use BMI or another body-composition measure in the prespecified statistical model;
• or design dose and power assumptions to accommodate a potentially smaller response in participants with obesity.

The least defensible option is to ignore the issue and interpret a weak average increase as proof that the fortified food delivered no biologically useful dose.

BMI is also an imperfect proxy. It does not distinguish fat mass from lean mass and may not capture the distribution of adipose tissue. Depending on the study population and available resources, waist circumference, body weight, body-composition estimates or other anthropometric measures may add useful context. The protocol does not need to become a metabolic phenotyping project, but it should identify which measure is being used and why.

Co-nutrient status introduces another layer. Vitamin D does not operate in isolation from the rest of the diet. Calcium intake, magnesium status, protein adequacy and overall energy intake can affect bone-related outcomes, adherence and the interpretation of symptoms or functional measures. These variables do not need to be treated as automatic exclusion criteria. In many cases, measuring them is more informative than trying to remove every participant with an imperfect diet.

A practical baseline assessment may include:

• a food-frequency questionnaire or repeated dietary recalls;
• current use of vitamin D, calcium and multivitamin supplements;
• relevant medical conditions and medications;
• usual sun exposure and clothing practices;
• body weight, height and BMI;
• markers selected to support the study’s outcome, where appropriate;
• and a record of recent changes in diet or fortified-food consumption.

These measurements serve two purposes. First, they can identify an imbalance between randomized groups. Second, they show whether the intervention is being tested against a stable background. If participants begin consuming additional supplements during follow-up, the fortification intervention is no longer the only meaningful source of vitamin D.

Adherence should be treated with the same seriousness. In a food-fortification study, adherence is not simply whether a participant remembers to swallow a capsule. It may involve consuming the assigned food, consuming the intended portion, storing it correctly and avoiding substitution with an equivalent product. Returned product counts, consumption diaries, packaging records or biomarker-based checks may each contribute to the picture, depending on the design.

The result of these controls is not a perfectly uniform cohort. That is neither realistic nor necessary. The result is a cohort whose sources of variation are visible enough to model rather than silently allowing them to dilute the treatment estimate.

Standardizing Laboratory Assays via VDSP Protocols

A trial can have sensible eligibility criteria and still generate an unstable primary endpoint if its 25(OH)D measurements are not comparable. This is a particular concern in multicenter research, where different laboratories may use different platforms, calibration systems, reagent lots and quality-control procedures.

Immunoanalytical methods, including chemiluminescence assays, ELISA and RIA, can show meaningful differences when measuring the same sample. The size and direction of the discrepancy vary by platform and analyte concentration. A value that looks like a small biological difference may instead reflect analytical variation. When such measurements are pooled across sites, the added noise can widen confidence intervals and obscure a real but modest treatment effect.

That does not mean every immunoassay is unusable. It means the method must be evaluated for the purpose of the trial. A method that is acceptable for routine clinical monitoring may not provide the same level of comparability required for a multicenter intervention study with a relatively small expected change.

The Vitamin D Standardization Program, coordinated through the NIH Office of Dietary Supplements, provides a framework for improving comparability. Reference materials and procedures linked to reference measurement systems, including LC-MS/MS-based methods, can be used to assess whether a participating laboratory’s results are aligned with standardized values. In retrospective standardization, a set of single-donor serum samples with assigned reference values can support the development of a conversion equation for the assay in use.

The operational details should be written into the protocol rather than left to the central laboratory’s general quality statement. At minimum, the research team should decide:

1. Which laboratory or laboratories will analyze the samples.

2. Which assay platform and version will be used.

3. Whether samples from the same participant will be analyzed in the same run where feasible.

4. How calibration and quality-control materials will be documented.

5. How between-site and between-batch variation will be monitored.

6. What will happen if a laboratory changes platform, reagent lot or calibration procedure during the trial.

7. Whether stored samples can be reanalyzed using a standardized method if a concern emerges.

A VDSP-aligned reference panel can be run before recruitment or randomization begins. Periodic monitoring during the trial can help identify drift rather than discovering it after the database has closed. The exact schedule should reflect the duration, number of sites, assay platform and expected operational changes; a fixed calendar interval is not a substitute for a quality-control plan.

A 25(OH)D value is only as useful as the calibration system that makes it comparable with the next value.

The statistical analysis should acknowledge assay uncertainty as well. If the laboratory method has known imprecision, the sample-size calculation should not be based on an unrealistically clean biomarker. If multiple sites are involved, site can be included in the model, and sensitivity analyses can examine whether the treatment estimate changes after adjustment for laboratory or platform.

Standardization also protects against a more subtle error: confusing a change in measurement with a change in physiology. If the intervention group is measured on one platform and the control group on another, or if a platform changes halfway through follow-up, the endpoint can be biased even when participant handling is flawless. Laboratory methods belong in the causal architecture of the trial, not in a technical appendix that no one revisits.

Vehicle Stability and Bioavailability in Fortification Research

The food vehicle is part of the intervention. A label claim describes the amount of cholecalciferol added during manufacture; it does not automatically describe the amount remaining when the food reaches the participant, how evenly it is distributed or how much is absorbed after consumption.

The matrix can influence stability, homogeneity and release in the gastrointestinal tract. Packaging, temperature, humidity, light exposure, production conditions and storage time may all affect the delivered dose. The relevant question is not whether the product was correctly manufactured on day one. It is whether the product still delivers a consistent and absorbable amount under the conditions in which the intervention will actually be used.

Granulated sugar has been examined as a potential fortification vehicle, but the performance of any vehicle depends on formulation and storage conditions. A stability result obtained under controlled laboratory conditions cannot simply be transferred to a humid environment, a long distribution chain or household storage without additional validation. If the field setting differs from the manufacturing setting, the stability study should reflect that difference.

Three kinds of evidence are especially important.

Stability under realistic storage conditions

Accelerated stability testing can help identify likely degradation pathways, while real-time testing shows what happens over the intended shelf life. Both are more useful when the temperature, humidity, packaging and handling resemble deployment conditions. The protocol should define acceptable potency loss and explain how out-of-specification batches will be handled.

Homogeneity across the product

A fortified food can contain the correct average amount of vitamin D while still distributing it unevenly between units. Sampling should therefore examine multiple production batches and multiple units within batches. The relevant question is not only whether the mean concentration meets the target, but also whether individual servings are reasonably consistent.

Bioavailability in the target population

A food matrix is not automatically equivalent to an oil-based supplement. Fat-soluble vitamin absorption can depend on the composition of the meal, the physical form of the nutrient, emulsification, gastrointestinal conditions and individual variation. The difference may be small or substantial depending on the formulation, but it should be measured rather than assumed away.

A pilot feeding study can compare the serum response to the selected vehicle in the population that the main trial is intended to represent. The pilot does not need to reproduce the full efficacy study. Its purpose is to establish whether the planned food vehicle produces a measurable and sufficiently consistent biomarker response, and to identify operational problems before a large trial begins.

The pilot should specify the timing of blood collection, the assay method, the food portion, the accompanying meal conditions and the storage history of the test product. Without those details, a low response could reflect poor absorption, an insufficient dose, degradation during storage, inconsistent consumption or an analytical problem.

Skipping a bioavailability pilot does not make the subsequent trial worthless. It makes a null result harder to interpret. If serum 25(OH)D does not change, the intervention may have been biologically ineffective, poorly absorbed, degraded before consumption or consumed inconsistently. The design should give the investigators a way to distinguish among those explanations.

Aligning Intervention Targets with EFSA Intake Guidelines

The European Food Safety Authority’s Adequate Intake for vitamin D is 15 µg per day, or 600 IU, for healthy individuals over one year of age, including pregnant and lactating women. This reference point can help anchor a fortification study, but it is not a universal dose-response guarantee. An Adequate Intake is a population-level reference, not a promise that every participant receiving that amount will reach the same serum concentration.

The protocol should explain how the intervention dose relates to the public-health question. Is the study testing a food designed to supplement ordinary intake? Is it intended to close a gap in a population with low sun exposure? Is the goal to maintain status, correct low status or evaluate a clinical outcome? Each purpose may justify a different dose and duration.

Three design principles follow.

• Justify the dose against the relevant intake reference. If the dose is below, near or above 15 µg per day, the protocol should explain why. The rationale should connect the amount added to the food, expected background intake and the population’s baseline status.
• Define the serum target without treating it as the only endpoint. A shift in 25(OH)D can confirm biological exposure, while bone, immune or functional outcomes address the intervention’s practical importance. A target range such as 75–100 nmol/L may be relevant to a specific outcome framework, but the protocol should explain the evidence supporting that range rather than presenting it as a universal threshold.
• Allow enough time for the biomarker and clinical endpoint to respond. Serum 25(OH)D changes over weeks, and a study lasting only a short period may capture an incomplete response. An intervention period of roughly 8–12 weeks may be useful for observing approach to a new steady state, but the required duration depends on the dose, baseline status, outcome and sampling schedule.

The distinction between a scientific dose and a policy dose is central. A high-dose supplement can demonstrate that serum 25(OH)D is biologically responsive, yet tell policymakers little about a low-dose fortification program. Conversely, a modest food-fortification dose may be highly relevant to population policy even if its effect in an individual participant is smaller and more variable.

Dose-response analysis should therefore be planned across the range that the intervention is expected to produce. Measuring only whether the mean concentration changed can miss a non-linear response or a stronger effect among participants with low baseline status. The analysis may include baseline concentration, BMI, adherence, season and dietary intake as effect modifiers or covariates, provided these roles are defined before the data are examined.

The safety framework also needs to match the dose. The protocol should record additional vitamin D exposure, adverse events, relevant medications and any laboratory measures required for the population and intervention. A policy-relevant dose is not simply one that raises 25(OH)D; it is one whose expected benefit, safety and feasibility can be evaluated under realistic conditions.

What the Protocol Must Make Explicit

The following table is not a substitute for the full protocol. It is a way to expose the decisions that are often left implicit until the study is already under way.

The most important feature of this table is not the number of rows. It is the connection between them. A baseline threshold affects the expected response. The expected response affects power. BMI and assay variation affect the variance used in that calculation. Vehicle stability affects the dose actually delivered. Adherence affects the exposure actually received. Treating each item as an isolated checkbox misses the way the design behaves as a system.

The Verdict

Clinical trial protocol design for vitamin D fortification is demanding because the intervention is embedded in biology, diet and real-world food distribution. The solution is not to force a nutritional study into a pharmaceutical template. It is to define the biological starting point, anticipate the variables that can modify response, validate the food vehicle and measure the biomarker with a method that can support comparison.

Replete participants may still show an increase in 25(OH)D, but their clinical response may be smaller or more difficult to detect. Participants with obesity may respond differently to the same administered dose, but their inclusion does not automatically flatten the dose-response curve or invalidate the trial. An unstandardized assay can weaken the endpoint, but it does not erase every observation made with that assay. A vehicle without a bioavailability pilot can make a negative result ambiguous, yet the result may still contribute evidence when the exposure and limitations are carefully described.

That is the more useful interpretation of a poorly designed vitamin D trial. Its weaknesses reduce confidence in the size, mechanism or generalizability of the finding. They do not justify rewriting every null result as meaningless, and they do not permit a positive result to carry more certainty than the measurement system can support.

The final protocol should make the chain of exposure visible: who entered the study, what their vitamin D status was, how much cholecalciferol was present when the food was consumed, how much was likely absorbed, how serum 25(OH)D was measured and which clinical outcome was expected to move. If any link is uncertain, the analysis should say so.

Fortification policy built on this kind of evidence will still encounter biological variation and imperfect adherence. That is unavoidable. What is avoidable is allowing baseline status, body composition, laboratory calibration or food stability to remain hidden sources of uncertainty. In vitamin D research, methodological discipline does not make the question less interesting. It is what allows the result to answer the question at all.